Janssen gets expanded authorization for Genmab's Darzalex in EU

On Tuesday, the EU Commission approved Genmab's Darzalex for treating the rare disease light-chain amyloidosis.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's collaborative partner Janssen has received a European marketing Authorization for Darzalex for treating the rare disease Light-chain (AL) amyloidosis.

The EU Commission has reached this decision on Tuesday after an expert panel recommended approving Darzalex in May.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs